PLK1 and acute myeloid leukemia: For all these reasons, in recent years, PLK1 has become an interesting therapeutic target in oncology [28,29,30], and several PLK1 inhibitors have indeed been developed and are under clinical investigation [31], including volasertib in phase III study in acute myeloid leukemia [32], and onvansertib, undergoing investigation in phase II in combination with other drugs (https://trovageneoncology.com/pipeline/).